Vir Biotechnology IncVIR

VIR current price
$7.43-25.20%

Capital at risk.

1W
-9.50%
1M
-17.08%
3M
-5.34%
6M
-18.85%
1Y
-25.20%
MAX
-46.86%
About Vir Biotechnology Inc
Ticker
info
VIR
Trading on
info
NASDAQ
ISIN
info
US92764N1028
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Headquarters
info
1800 Owens Street, San Francisco, CA, United States, 94158
Employees
info
587
Website
info
vir.bio
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Metrics
BasicAdvanced
Market cap
info
$1.08B
P/E ratio
info
-
EPS
info
-$3.73
Dividend Yield
info
0.00%
Beta
info
0.46
Forward P/E ratio
info
4.36
EBIDTA
info
$-534M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.08B
Average daily volume
info
1.6M
90-day return
info
-5.34%
30-day return
info
-17.08%
7-day return
info
-9.50%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
4.36
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
13.7
Price to book
info
0.82
Earnings
EPS
info
-$3.73
EPS estimate (current quarter)
info
-$1.05
EPS estimate (next quarter)
info
-$0.89
EBITDA
info
$-534M
Revenues (TTM)
info
$78.6M
Revenues per share (TTM)
info
$0.58
Technicals
Beta
info
0.46
52-week High
info
$13.09
52-week Low
info
$6.56
50-day moving average
info
$8.03
200-day moving average
info
$9.02
Short ratio
info
4.15
Short %
info
7.26%
Management effectiveness
ROE (TTM)
info
36.58%
ROA (TTM)
info
19.41%
Profit margin
info
0.00%
Gross profit margin
info
$1.03B
Operating margin
info
9,184.54%
Growth
Quarterly earnings growth (YoY)
info
58.50%
Quarterly revenue growth (YoY)
info
9.80%
Share stats
Outstanding Shares
info
138M
Float
info
92.5M
Insiders %
info
11.90%
Institutions %
info
75.31%
Analyst Insights & forecasts
info

67% Buy

33% Hold

0% Sell

Based on information from 9 analysts.

Average price target

info
$29.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.86
-$1.01
14.85%
Q4 • 23Beat
-$0.48
-$1.05
54.29%
Q1 • 24Beat
-$1.02
-$0.90
13.33%
Q2 • 24Beat
-$1.56
-$1.05
48.57%
Q3 • 24Beat
-
-$0.89
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$3.1M
$-138M
4,500.10%
Q2 • 24
$2.4M
$-214M
8,979.71%
Q3 • 24
22.60%
54.44%
99.54%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$1.67B
$236M
14.13%
Q2 • 24
$1.5B
$258M
17.19%
Q3 • 24
10.25%
9.22%
21.70%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-77.8M
$212M
$2.9M
$-78.5M
Q2 • 24
$-171M
$119M
$0M
$-174M
Q3 • 24
120.28%
43.95%
98.95%
121.41%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Greed

+1.5

0.38

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Vir Biotechnology Inc share?
Collapse

Vir Biotechnology Inc shares are currently traded for $7.43 per share.

How many shares does Vir Biotechnology Inc have?
Collapse

Vir Biotechnology Inc currently has 138M shares.

Does Vir Biotechnology Inc pay dividends?
Collapse

No, Vir Biotechnology Inc doesn't pay dividends.

What is Vir Biotechnology Inc 52 week high?
Collapse

Vir Biotechnology Inc 52 week high is $13.09.

What is Vir Biotechnology Inc 52 week low?
Collapse

Vir Biotechnology Inc 52 week low is $6.56.

What is the 200-day moving average of Vir Biotechnology Inc?
Collapse

Vir Biotechnology Inc 200-day moving average is $9.02.

Who is Vir Biotechnology Inc CEO?
Collapse

The CEO of Vir Biotechnology Inc is Dr. Marianne De Backer M.B.A., M.Sc., Ph.D..

How many employees Vir Biotechnology Inc has?
Collapse

Vir Biotechnology Inc has 587 employees.

What is the market cap of Vir Biotechnology Inc?
Collapse

The market cap of Vir Biotechnology Inc is $1.08B.

What is the P/E of Vir Biotechnology Inc?
Collapse

The current P/E of Vir Biotechnology Inc is null.

What is the EPS of Vir Biotechnology Inc?
Collapse

The EPS of Vir Biotechnology Inc is -$3.73.

What is the PEG Ratio of Vir Biotechnology Inc?
Collapse

The PEG Ration of Vir Biotechnology Inc is null.

What do analysts say about Vir Biotechnology Inc?
Collapse

According to the analysts Vir Biotechnology Inc is considered a buy.

Vir Biotechnology Inc news